SHARE NOW
Clinical-stage biotechnology company Verve Therapeutics, Inc. has announced the expansion of its relationship with Eli Lily and Company (Lily).
Lily has purchased product rights to Verve’s cardiovascular in vivo gene editing programs targeting PCSK9 and ANGPTL3 and an additional third undisclosed cardiovascular disease (CVD) target. VERVE-101 and VERVE-102, the product candidates of PCSK9 alongside VERVE-201, ANGPTL3 product candidate, are designed to potently and durably lower low-density lipoprotein cholesterol throughout the lifetime of patients with or at risk for the most common form of CVD, atherosclerosis cardiovascular disease (ASCVD).
PhD, group vice president, of diabetes, obesity and cardiometabolic research at Lilly, Ruth Gimeno expressed the need for the strategic partnership, stating that:
“Verve is a leader in developing gene editing therapies for cardiovascular disease, and we are pleased to expand our relationship with Verve to develop much needed new treatment options for people with cardiovascular disease.”
Lilly has acquired the product rights that were previously held by Beam Therapeutics. This includes the right to share development expenses equally (33%) and jointly commercialize as well as share profits and expenses related to commercialization in the United States for PCSK9 and ANGPTL3 product candidates.
How are you enjoying this news article? Let us know your thoughts, here >>
“We are thrilled to gain Lilly as a potential long-term partner for the next stage of development of our gene editing medicines for people with ASCVD,” shared Sekar Kathiresan, M.D., co-founder and CEO of Verve. “Lilly brings valuable know-how in the cardiometabolic space, as well as commercialization expertise of products for large indications.”
Verve retains all product rights for the PCSK9 and ANGPTL3 programs outside the United States. Additionally, under the collaboration agreement, Verve retains control of the development and commercialization of all collaboration products.
Beam’s right to opt-in to co-fund and share potential profits on similar terms for a third undisclosed CVD target has also been acquired by Lilly.
“Lilly’s significant investment in acquiring Beam’s product rights confirms Lilly’s confidence in Verve’s programs and the supporting preclinical and interim clinical data,” continued Kathiresan. “We continue to be impressed by Lilly’s commitment to genetic medicines, and their team’s interest in applying gene editing technology to the cardiometabolic space closely aligns with Verve’s vision.”
This expansion of the relationship between Verve and Lilly follows a previous research collaboration in June 2023 focused on advancing Verve’s preclinical stage in vivo gene editing program targeting lipoprotein(a).
Source: Verve Therapeutics Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
